Vascular smooth muscle contractile machinery (VSMC contractile machinery)

The vascular smooth muscle contractile machinery is a complex integrated system of proteins responsible for the mechanical contraction and relaxation of blood vessel walls, which directly regulates vascular resistance and systemic blood pressure. The primary components of this machinery include thick filaments composed of Myosin II and thin filaments composed of Actin, along with regulatory enzymes such as Myosin Light Chain Kinase (MLCK) and Myosin Light Chain Phosphatase (MLCP) [1][2]. Contraction is triggered by an increase in intracellular calcium, which binds to calmodulin to activate MLCK, leading to the phosphorylation of the 20-kDa myosin light chain (MLC20) and subsequent cross-bridge cycling [3]. Relaxation is mediated by MLCP-induced dephosphorylation of MLC20, a process heavily influenced by the Nitric Oxide/cGMP pathway and the Rho-kinase (ROCK) pathway, the latter of which increases calcium sensitivity by inhibiting MLCP [4][5]. Dysregulation of these contractile proteins and their regulatory pathways is a central factor in the pathogenesis of hypertension and vasospastic disorders [5]. Therapeutic agents target this machinery through various nodes, such as calcium channel blockers that limit calcium entry or nitrates that enhance MLCP activity via cGMP, to alleviate pathological vasoconstriction [6]. (Citations: [1] Webb, R. C. (2003) Adv Physiol Educ; [2] Somlyo, A. P., & Somlyo, A. V. (2003) Physiol Rev; [3] Kamm, K. E., & Stull, J. T. (1985) Annu Rev Pharmacol Toxicol; [4] Grassie, M. E., et al. (2011) J Muscle Res Cell Motil; [5] Touyz, R. M., et al. (2018) Cardiovasc Res; [6] Fukata, Y., et al. (2001) Trends Pharmacol Sci).

Other names

Smooth muscle contractile apparatusMyosin-actin contractile unitVascular contractile machinerySmooth muscle motor complex

Inhibition of L-type calcium channels to prevent MLCK activation; stimulation of soluble guanylate cyclase to increase cGMP and activate MLCP; direct inhibition of Rho-kinase (ROCK) to prevent MLCP inhibition; direct inhibition of Myosin Light Chain Kinase (MLCK).